Jivan Shakya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jivan Shakya has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Michal Amit Rahat
Immunotherapy Laboratory, Carmel Medical Center, Haifa 3436212, Israel
3 shared publications - Dibesh Karmacharya
Center for Molecular Dynamics Nepal, Thapathali, Nepal
2 shared publications Manisha Bista
Center for Molecular Dynamics Nepal, Thapathali
2 shared publicationsMarcella J. Kelly
Virginia Tech
2 shared publications- Padma Shrestha
Central Department of Microbiology, Tribhuvan University, Kirtipur, Nepal
2 shared publications - Reshma Tuladhar
Central Department of Microbiology, Tribhuvan University, Kathmandu, Nepal
2 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (11) , e0361369
Tiger abundance and density estimates from non-invasive sources: Camera-trap and genetic capture-recapture analyses
We present tiger density and abundance estimates derived independently from two non-invasive sampling techniques: camera-trapping and fecal genetic sampling in same geographic areas. Camera-trap data collected in 2009 covered 359.2 km 2 of lowland core area of Chitwan National Park using 187 camera-trap locations and 2,821 trap-nights obtaining 264 identifiable photographs of 41 tigers with 103 recaptures. Fecal genetic sampling in 2011 surveyed 325 km 2 along three spatial routes covering 1,173 km and collecting 257 tiger fecal samples. An eight multi-locus genotyping assay identified 31 tigers with 42 recaptures. We analyzed each dataset separately using spatially explicit capture-recapture models under Maximum likelihood and Bayesian framework. Maximum Likelihood-based density estimates from DENSITY were 2.55 (SE 0.6) tigers per 100 km² for camera traps and 2.57 (SE 0.9) for genetic data, while Bayesian estimates from SPACECAP were slightly lower at 2.4 (SE 0.3) and 2.2 (SE 0.5), respectively. Maximum Likelihood abundance estimates were 66 (SE 7.9) for camera data and 88 (SE 19.3) for genetic data, whereas Bayesian estimates were 64 (SE 7.9) and 93 (SE 19), respectively. Two independent data sources broadly comparable density estimates, though uncertainty was greater for the genetic dataset, which included fewer identified individuals and spatial recaptures. Because the data were surveyed in different years and differed in sampling effort, differences in precision cannot be attributed solely to sampling method. Non-invasive genetic sampling nonetheless produced density and abundance estimates broadly consistent with an established camera trap protocol, suggesting that integrating the data sources can enhance robust tiger monitoring and inform effective conservation planning.
- 4 November 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (11) , e0361369
Open AccessTiger abundance and density estimates from non-invasive sources: Camera-trap and genetic capture-recapture analyses
We present tiger density and abundance estimates derived independently from two non-invasive sampling techniques: camera-trapping and fecal genetic sampling in same geographic areas. Camera-trap data collected in 2009 covered 359.2 km 2 of lowland core area of Chitwan National Park using 187 camera-trap locations and 2,821 trap-nights obtaining 264 identifiable photographs of 41 tigers with 103 recaptures. Fecal genetic sampling in 2011 surveyed 325 km 2 along three spatial routes covering 1,173 km and collecting 257 tiger fecal samples. An eight multi-locus genotyping assay identified 31 tigers with 42 recaptures. We analyzed each dataset separately using spatially explicit capture-recapture models under Maximum likelihood and Bayesian framework. Maximum Likelihood-based density estimates from DENSITY were 2.55 (SE 0.6) tigers per 100 km² for camera traps and 2.57 (SE 0.9) for genetic data, while Bayesian estimates from SPACECAP were slightly lower at 2.4 (SE 0.3) and 2.2 (SE 0.5), respectively. Maximum Likelihood abundance estimates were 66 (SE 7.9) for camera data and 88 (SE 19.3) for genetic data, whereas Bayesian estimates were 64 (SE 7.9) and 93 (SE 19), respectively. Two independent data sources broadly comparable density estimates, though uncertainty was greater for the genetic dataset, which included fewer identified individuals and spatial recaptures. Because the data were surveyed in different years and differed in sampling effort, differences in precision cannot be attributed solely to sampling method. Non-invasive genetic sampling nonetheless produced density and abundance estimates broadly consistent with an established camera trap protocol, suggesting that integrating the data sources can enhance robust tiger monitoring and inform effective conservation planning.
- Open Access
Lytic bacteriophages against Salmonella Typhi as a potential alternative to antibiotics
Introduction: Enteric fever, being endemic with seasonal peaks in low- and middle-income countries, is a major health concern. Moreover, the rise in antibiotic resistance has exacerbated the situation. This study was undertaken to investigate the lytic bacteriophages against Salmonella Typhi with a potential for phage therapy. Materials and Methods: A hospital-based cross-sectional study was conducted from October 2023 to March 2024. Blood cultures were processed by the BACTEC automated culture system following standard microbiological techniques to isolate typhoidal Salmonella . Antibiotic susceptibility was tested by the modified Kirby-Bauer disc diffusion method. Lytic bacteriophages isolated by the double-layer agar method were assessed for their host range and lytic ability with spot and turbidimetric assays. Results: Of the total 1054 blood specimens, 35 (3.2%) were positive for S. Typhi . All the isolates were susceptible to first-line antibiotics—ampicillin, chloramphenicol, and cotrimoxazole. The isolates were also sensitive to nalidixic acid (80%) as well as fluoroquinolones; ciprofloxacin (62.86%), levofloxacin (77.14%), and ofloxacin (80%). Fifteen lytic phages were isolated against S. Typhi Ty2 and CT18 strains. Four phages—vB_SaTy_ST2, vB_SaTy_ST7, vB_SaTy_ST17, and vB_SaTy_ST18—lysed all 35 clinical S. Typhi isolates. While vB_SaTy_ST17 and vB_SaTy_ST18 also lysed 7 out of 20 S. Paratyphi A isolates. Three phages (vB_SaTy_ST2, vB_SaTy_ST7, vB_SaTy_ST17) were tested against S. Typhi isolate S30. Individually, vB_SaTy_ST17 suppressed the growth for 13 hours, vB_SaTy_ST2 and vB_SaTy_ST7 for 10 hours. The phage cocktail vB_SaTy_ST2 + vB_SaTy_ST17 was the most effective, which extended the inhibition time to 15 hours. Conclusion: This study highlights the ongoing burden of enteric fever in Nepal and the increase in susceptibility of S . Typhi to nalidixic acid and fluoroquinolones. It also demonstrates the promising lytic potential of bacteriophages, particularly vB_SaTy_ST17 and the phage cocktail vB_SaTy_ST2 + vB_SaTy_ST17, against clinical S. Typhi, highlighting their potential as alternatives to antibiotics.
Open AccessLytic bacteriophages against Salmonella Typhi as a potential alternative to antibiotics
Introduction: Enteric fever, being endemic with seasonal peaks in low- and middle-income countries, is a major health concern. Moreover, the rise in antibiotic resistance has exacerbated the situation. This study was undertaken to investigate the lytic bacteriophages against Salmonella Typhi with a potential for phage therapy. Materials and Methods: A hospital-based cross-sectional study was conducted from October 2023 to March 2024. Blood cultures were processed by the BACTEC automated culture system following standard microbiological techniques to isolate typhoidal Salmonella . Antibiotic susceptibility was tested by the modified Kirby-Bauer disc diffusion method. Lytic bacteriophages isolated by the double-layer agar method were assessed for their host range and lytic ability with spot and turbidimetric assays. Results: Of the total 1054 blood specimens, 35 (3.2%) were positive for S. Typhi . All the isolates were susceptible to first-line antibiotics—ampicillin, chloramphenicol, and cotrimoxazole. The isolates were also sensitive to nalidixic acid (80%) as well as fluoroquinolones; ciprofloxacin (62.86%), levofloxacin (77.14%), and ofloxacin (80%). Fifteen lytic phages were isolated against S. Typhi Ty2 and CT18 strains. Four phages—vB_SaTy_ST2, vB_SaTy_ST7, vB_SaTy_ST17, and vB_SaTy_ST18—lysed all 35 clinical S. Typhi isolates. While vB_SaTy_ST17 and vB_SaTy_ST18 also lysed 7 out of 20 S. Paratyphi A isolates. Three phages (vB_SaTy_ST2, vB_SaTy_ST7, vB_SaTy_ST17) were tested against S. Typhi isolate S30. Individually, vB_SaTy_ST17 suppressed the growth for 13 hours, vB_SaTy_ST2 and vB_SaTy_ST7 for 10 hours. The phage cocktail vB_SaTy_ST2 + vB_SaTy_ST17 was the most effective, which extended the inhibition time to 15 hours. Conclusion: This study highlights the ongoing burden of enteric fever in Nepal and the increase in susceptibility of S . Typhi to nalidixic acid and fluoroquinolones. It also demonstrates the promising lytic potential of bacteriophages, particularly vB_SaTy_ST17 and the phage cocktail vB_SaTy_ST2 + vB_SaTy_ST17, against clinical S. Typhi, highlighting their potential as alternatives to antibiotics.
- Open Access
- 17 June 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15 (1) , e88069
Dovramilast for Erythema Nodosum Leprosum in Patients With Leprosy in Nepal: Protocol for a Phase 2 Open-Label Pilot Study
Background: Erythema nodosum leprosum (ENL) is an immunological complication affecting up to 10% of borderline lepromatous and 50% of lepromatous leprosy cases with a high bacterial index (3‐6+). Current treatments often require prolonged therapy over years and cause significant long-term side effects, highlighting the need for new therapies. Therefore, it is imperative to identify new therapies for ENL. Phosphodiesterase 4 inhibitors are a class of compounds that mediate immune homeostasis and have the potential to treat ENL with fewer side effects. Dovramilast (formerly CC-11050) is an anti-inflammatory phosphodiesterase 4 inhibitor; to date, it has been shown to be well tolerated in phase 1 human studies. This is the first phase 2 study of dovramilast in ENL. Objective: This phase 2 pilot study aims to assess the safety and tolerability of dovramilast and to explore preliminary clinical responses in patients with new or recurrent ENL. Methods: This study was designed in two steps: (1) 28 days of treatment for 10 males to ensure safety and (2) an initial 12-week treatment course, with the option to retreat if further ENL episodes occur (up to 48 wk of treatment), for up to 40 males or females, as required on a case-by-case basis. Demographic, clinical, and laboratory data will be collected longitudinally, along with the ENL International Study Group ENL Severity Scale, Brief Pain Inventory, and Douleur Neuropathique 4 questionnaire for the identification of neuropathic pain. Patients will be followed for 12 months for ENL recurrence after cessation of the study drug. Safety will be evaluated through adverse event reporting and laboratory monitoring, while efficacy will be assessed using descriptive and trend-based analyses of changes in ENL severity, pain, and clinical outcomes over time. Results: The initial safety evaluation (step 1) of this phase 2 pilot study was completed and reviewed by an independent Data Safety Monitoring Board, which did not identify safety concerns that would preclude continuation of the study. Based on the step 1 results, the study proceeded to step 2, which evaluates longer-term administration of dovramilast in male and female participants. As of April 2026, a total of 15 participants have been recruited. All study data are anticipated to be collected by September 2027, with publication of the main trial results expected by December 2027. Conclusions: This phase 2 pilot study is designed to generate preliminary data on the safety, tolerability, and potential clinical signals of dovramilast in patients with new or recurrent ENL. Findings from this exploratory trial will inform the feasibility, outcome measures, and design of future adequately powered randomized controlled studies and do not directly support changes to current clinical practice at this stage.
- 17 June 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15 (1) , e88069
Open AccessDovramilast for Erythema Nodosum Leprosum in Patients With Leprosy in Nepal: Protocol for a Phase 2 Open-Label Pilot Study
Background: Erythema nodosum leprosum (ENL) is an immunological complication affecting up to 10% of borderline lepromatous and 50% of lepromatous leprosy cases with a high bacterial index (3‐6+). Current treatments often require prolonged therapy over years and cause significant long-term side effects, highlighting the need for new therapies. Therefore, it is imperative to identify new therapies for ENL. Phosphodiesterase 4 inhibitors are a class of compounds that mediate immune homeostasis and have the potential to treat ENL with fewer side effects. Dovramilast (formerly CC-11050) is an anti-inflammatory phosphodiesterase 4 inhibitor; to date, it has been shown to be well tolerated in phase 1 human studies. This is the first phase 2 study of dovramilast in ENL. Objective: This phase 2 pilot study aims to assess the safety and tolerability of dovramilast and to explore preliminary clinical responses in patients with new or recurrent ENL. Methods: This study was designed in two steps: (1) 28 days of treatment for 10 males to ensure safety and (2) an initial 12-week treatment course, with the option to retreat if further ENL episodes occur (up to 48 wk of treatment), for up to 40 males or females, as required on a case-by-case basis. Demographic, clinical, and laboratory data will be collected longitudinally, along with the ENL International Study Group ENL Severity Scale, Brief Pain Inventory, and Douleur Neuropathique 4 questionnaire for the identification of neuropathic pain. Patients will be followed for 12 months for ENL recurrence after cessation of the study drug. Safety will be evaluated through adverse event reporting and laboratory monitoring, while efficacy will be assessed using descriptive and trend-based analyses of changes in ENL severity, pain, and clinical outcomes over time. Results: The initial safety evaluation (step 1) of this phase 2 pilot study was completed and reviewed by an independent Data Safety Monitoring Board, which did not identify safety concerns that would preclude continuation of the study. Based on the step 1 results, the study proceeded to step 2, which evaluates longer-term administration of dovramilast in male and female participants. As of April 2026, a total of 15 participants have been recruited. All study data are anticipated to be collected by September 2027, with publication of the main trial results expected by December 2027. Conclusions: This phase 2 pilot study is designed to generate preliminary data on the safety, tolerability, and potential clinical signals of dovramilast in patients with new or recurrent ENL. Findings from this exploratory trial will inform the feasibility, outcome measures, and design of future adequately powered randomized controlled studies and do not directly support changes to current clinical practice at this stage.
- Open Access
- 9 October 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (10) , e0334139
Bacteriophage as an anti-biofilm agent against Pseudomonas aeruginosa from wound infection
Pseudomonas aeruginosa, an opportunistic pathogen associated with wound infections, resists many commonly available antibiotics. Its ability to form biofilm provides an additional trait to evade antibiotics. Biofilm-associated infections are difficult to treat, raising the need for alternative strategies. Thus, this research aimed to investigate the potential of bacteriophage to disrupt the biofilm produced by P. aeruginosa isolated from wound infections. Wound samples were collected aseptically, processed for the isolation of P. aeruginosa, and identified by standard microbiological methods. Antimicrobial susceptibility was determined by the Kirby-Bauer disc diffusion method. Bacteriophages were isolated using the double-layer agar method. Phenotypic assessment of biofilm formation by the isolates and its reduction by phages was conducted by the tissue culture plate assay. Out of 647 wound samples processed, 96 P. aeruginosa were isolated. Piperacillin/tazobactam was the most effective antibiotic, while doxycycline was the least effective. Among the total isolates, 86 (89.6%) were multidrug-resistant (MDR) and 69 (71.9%) were biofilm producers. Three different phages isolated from sewage demonstrated a high specificity to P. aeruginosa. Of these, phage vB_PaeP_PS2 lysed the highest number of isolates (22.9%), including 17 MDR and 21 biofilm-producing isolates. The biofilm reduction assay demonstrated that phage treatment significantly reduced biofilm formation, with vB_PaeP_PS2 achieving a 58% reduction after 6 h of treatment. In conclusion, this study highlights the high prevalence of biofilm-producing MDR P. aeruginosa in wound infections and, for the first time in Nepal, demonstrates the potential of locally isolated phages to lyse biofilm-forming MDR isolates and disrupt their biofilms.
- 9 October 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (10) , e0334139
Open AccessBacteriophage as an anti-biofilm agent against Pseudomonas aeruginosa from wound infection
Pseudomonas aeruginosa, an opportunistic pathogen associated with wound infections, resists many commonly available antibiotics. Its ability to form biofilm provides an additional trait to evade antibiotics. Biofilm-associated infections are difficult to treat, raising the need for alternative strategies. Thus, this research aimed to investigate the potential of bacteriophage to disrupt the biofilm produced by P. aeruginosa isolated from wound infections. Wound samples were collected aseptically, processed for the isolation of P. aeruginosa, and identified by standard microbiological methods. Antimicrobial susceptibility was determined by the Kirby-Bauer disc diffusion method. Bacteriophages were isolated using the double-layer agar method. Phenotypic assessment of biofilm formation by the isolates and its reduction by phages was conducted by the tissue culture plate assay. Out of 647 wound samples processed, 96 P. aeruginosa were isolated. Piperacillin/tazobactam was the most effective antibiotic, while doxycycline was the least effective. Among the total isolates, 86 (89.6%) were multidrug-resistant (MDR) and 69 (71.9%) were biofilm producers. Three different phages isolated from sewage demonstrated a high specificity to P. aeruginosa. Of these, phage vB_PaeP_PS2 lysed the highest number of isolates (22.9%), including 17 MDR and 21 biofilm-producing isolates. The biofilm reduction assay demonstrated that phage treatment significantly reduced biofilm formation, with vB_PaeP_PS2 achieving a 58% reduction after 6 h of treatment. In conclusion, this study highlights the high prevalence of biofilm-producing MDR P. aeruginosa in wound infections and, for the first time in Nepal, demonstrates the potential of locally isolated phages to lyse biofilm-forming MDR isolates and disrupt their biofilms.
- Open Access
- 3 July 2023
- Published by Scientific Scholar in Journal of Laboratory Physicians
- Vol. 15 (04) , 510-517
Effect of ABCA1-R219K Polymorphism in Serum Lipid Parameters in Patients under Statin Therapy Visiting Tertiary Cardiac Center of Nepal
Introduction ATP-binding cassette transporter A1 (ABCA1) encoded by ABCA1 gene is one of the important protein involved in lipid metabolism. The effect of statin therapy on dyslipidemia varies among individuals and it may be due to different genetic polymorphism. The R219K polymorphism of ABCA1 gene is found to have a significant role in the response of statin. Objective This study was designed to evaluate the effect of R219K polymorphism in lipid-lowering action of statin in patients with dyslipidemia. Material and Methods This study was conducted in 88 patients. Blood samples were taken from patients before and at the end of 3 months of statin use and were analyzed for lipid profile. Whole blood was analyzed for R219K Polymorphism using polymerase chain reaction-restriction fragment length polymorphism. Results R219K polymorphism was associated with significant percentage reduction of serum triglyceride/high-density lipoprotein (TG/HDL) ratio and total cholesterol/high-density lipoprotein (TC/HDL) ratio in atorvastatin users. However, there was no significant association of polymorphism with change in serum TC, HDL-C, LDL-C, TG, and very low-density lipoprotein (VLDL). Among KK genotype individuals, value of TG, VLDL, TG/HDL, and TC/HDL were significantly lower than in RR genotypes. Also, TG/HDL and TC/HDL were significantly lower in RK genotype than in RR. Treatment of dyslipidemia with statin was found to be comparatively better in patients having the genotypes KK and RK. Conclusion Our study demonstrated association of R219K polymorphism with the significant reduction of TG/HDL and TC/HDL and particularly the KK genotype was associated with significant improvement of lipid parameters following atorvastatin treatment.
- 3 July 2023
- Published by Scientific Scholar in Journal of Laboratory Physicians
- Vol. 15 (04) , 510-517
Open AccessEffect of ABCA1-R219K Polymorphism in Serum Lipid Parameters in Patients under Statin Therapy Visiting Tertiary Cardiac Center of Nepal
Introduction ATP-binding cassette transporter A1 (ABCA1) encoded by ABCA1 gene is one of the important protein involved in lipid metabolism. The effect of statin therapy on dyslipidemia varies among individuals and it may be due to different genetic polymorphism. The R219K polymorphism of ABCA1 gene is found to have a significant role in the response of statin. Objective This study was designed to evaluate the effect of R219K polymorphism in lipid-lowering action of statin in patients with dyslipidemia. Material and Methods This study was conducted in 88 patients. Blood samples were taken from patients before and at the end of 3 months of statin use and were analyzed for lipid profile. Whole blood was analyzed for R219K Polymorphism using polymerase chain reaction-restriction fragment length polymorphism. Results R219K polymorphism was associated with significant percentage reduction of serum triglyceride/high-density lipoprotein (TG/HDL) ratio and total cholesterol/high-density lipoprotein (TC/HDL) ratio in atorvastatin users. However, there was no significant association of polymorphism with change in serum TC, HDL-C, LDL-C, TG, and very low-density lipoprotein (VLDL). Among KK genotype individuals, value of TG, VLDL, TG/HDL, and TC/HDL were significantly lower than in RR genotypes. Also, TG/HDL and TC/HDL were significantly lower in RK genotype than in RR. Treatment of dyslipidemia with statin was found to be comparatively better in patients having the genotypes KK and RK. Conclusion Our study demonstrated association of R219K polymorphism with the significant reduction of TG/HDL and TC/HDL and particularly the KK genotype was associated with significant improvement of lipid parameters following atorvastatin treatment.
- Open Access
Emergence of IS Aba1 -linked oxacillinase genes among carbapenem resistant Acinetobacter baumannii isolates in a tertiary cardiac center, Nepal
Insertion sequence contributes to the emergence of carbapenem resistance by dissemination of carbapenemase genes and providing promoter for their overexpression. This study aims to ascertain the occurrence of IS Aba1 -linked OXA carbapenemase genes and its relevance to carbapenem resistance level in Acinetobacter baumannii . This hospital based descriptive study was conducted at Shahid Gangalal National Heart Center, Kathmandu, Nepal. An overall of 1,291 clinical specimens received for routine culture and antibiotic susceptibility testing throughout the study period were included in this study. Identification of Acinetobacter baumannii was validated through detection of intrinsic bla OXA-51-like gene by polymerase chain reaction (PCR). Antibiotic susceptibility was tested by Kirby-Bauer disc diffusion approach and minimum inhibitory concentration (MIC) of meropenem was assessed through agar dilution method. Uniplex PCR assays were performed to detect genes encoding oxacillinases and IS Aba1 . Upstream association of insertion element, IS Aba1 to oxacillinase genes was assessed through PCR mapping strategy using IS Aba1 F and OXA-51R/OXA-23R primers. Out of the 340 bacteria isolated, only 40 (11.8%) were Acinetobacter baumannii . All isolates were resistant against meropenem with MIC value ranging from 16-256 μg/ml. bla OXA-23-like genes was present in every isolate but bla OXA-58 in just two isolates (5%). All isolates had IS Aba1 either above bla OXA-23-like or bla OXA-51-like gene. Higher MIC 90 value of meropenem (243.20 μg/ml) was found in A . baumannii cluster with IS Aba1 -linked upstream to both bla OXA-23-like and bla OXA-51-like genes, thus depicting their eminent role to enhanced carbapenem resistance. Acinetobacter baumannii isolates with IS Aba1 -linked oxacillinase genes are rapidly emerging in clinical settings of Nepal. Thus, medical communities need to be prepared and enable targeted approaches for managing burgeoning problem of carbapenem resistance.
Open AccessEmergence of IS Aba1 -linked oxacillinase genes among carbapenem resistant Acinetobacter baumannii isolates in a tertiary cardiac center, Nepal
Insertion sequence contributes to the emergence of carbapenem resistance by dissemination of carbapenemase genes and providing promoter for their overexpression. This study aims to ascertain the occurrence of IS Aba1 -linked OXA carbapenemase genes and its relevance to carbapenem resistance level in Acinetobacter baumannii . This hospital based descriptive study was conducted at Shahid Gangalal National Heart Center, Kathmandu, Nepal. An overall of 1,291 clinical specimens received for routine culture and antibiotic susceptibility testing throughout the study period were included in this study. Identification of Acinetobacter baumannii was validated through detection of intrinsic bla OXA-51-like gene by polymerase chain reaction (PCR). Antibiotic susceptibility was tested by Kirby-Bauer disc diffusion approach and minimum inhibitory concentration (MIC) of meropenem was assessed through agar dilution method. Uniplex PCR assays were performed to detect genes encoding oxacillinases and IS Aba1 . Upstream association of insertion element, IS Aba1 to oxacillinase genes was assessed through PCR mapping strategy using IS Aba1 F and OXA-51R/OXA-23R primers. Out of the 340 bacteria isolated, only 40 (11.8%) were Acinetobacter baumannii . All isolates were resistant against meropenem with MIC value ranging from 16-256 μg/ml. bla OXA-23-like genes was present in every isolate but bla OXA-58 in just two isolates (5%). All isolates had IS Aba1 either above bla OXA-23-like or bla OXA-51-like gene. Higher MIC 90 value of meropenem (243.20 μg/ml) was found in A . baumannii cluster with IS Aba1 -linked upstream to both bla OXA-23-like and bla OXA-51-like genes, thus depicting their eminent role to enhanced carbapenem resistance. Acinetobacter baumannii isolates with IS Aba1 -linked oxacillinase genes are rapidly emerging in clinical settings of Nepal. Thus, medical communities need to be prepared and enable targeted approaches for managing burgeoning problem of carbapenem resistance.
- Open Access
- 29 July 2020
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 71 (Supplement) , S71-S78
Environmental Surveillance as a Tool for Identifying High-risk Settings for Typhoid Transmission
Enteric fever remains a major cause of morbidity in developing countries with poor sanitation conditions that enable fecal contamination of water distribution systems. Historical evidence has shown that contamination of water systems used for household consumption or agriculture are key transmission routes for Salmonella Typhi and Salmonella Paratyphi A. The World Health Organization now recommends that typhoid conjugate vaccines (TCV) be used in settings with high typhoid incidence; consequently, governments face a challenge regarding how to prioritize typhoid against other emerging diseases. A key issue is the lack of typhoid burden data in many low- and middle-income countries where TCV could be deployed. Here we present an argument for utilizing environmental sampling for the surveillance of enteric fever organisms to provide data on community-level typhoid risk. Such an approach could complement traditional blood culture-based surveillance or even replace it in settings where population-based clinical surveillance is not feasible. We review historical studies characterizing the transmission of enteric fever organisms through sewage and water, discuss recent advances in the molecular detection of typhoidal Salmonella in the environment, and outline challenges and knowledge gaps that need to be addressed to establish environmental sampling as a tool for generating actionable data that can inform public health responses to enteric fever.
- 29 July 2020
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 71 (Supplement) , S71-S78
Open AccessEnvironmental Surveillance as a Tool for Identifying High-risk Settings for Typhoid Transmission
Enteric fever remains a major cause of morbidity in developing countries with poor sanitation conditions that enable fecal contamination of water distribution systems. Historical evidence has shown that contamination of water systems used for household consumption or agriculture are key transmission routes for Salmonella Typhi and Salmonella Paratyphi A. The World Health Organization now recommends that typhoid conjugate vaccines (TCV) be used in settings with high typhoid incidence; consequently, governments face a challenge regarding how to prioritize typhoid against other emerging diseases. A key issue is the lack of typhoid burden data in many low- and middle-income countries where TCV could be deployed. Here we present an argument for utilizing environmental sampling for the surveillance of enteric fever organisms to provide data on community-level typhoid risk. Such an approach could complement traditional blood culture-based surveillance or even replace it in settings where population-based clinical surveillance is not feasible. We review historical studies characterizing the transmission of enteric fever organisms through sewage and water, discuss recent advances in the molecular detection of typhoidal Salmonella in the environment, and outline challenges and knowledge gaps that need to be addressed to establish environmental sampling as a tool for generating actionable data that can inform public health responses to enteric fever.
- Open Access
- 13 July 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-10
Modulation of anti-tumor immunity by the brain’s reward system
Regulating immunity is a leading target for cancer therapy. Here, we show that the anti-tumor immune response can be modulated by the brain’s reward system, a key circuitry in emotional processes. Activation of the reward system in tumor-bearing mice (Lewis lung carcinoma (LLC) and B16 melanoma) using chemogenetics (DREADDs), resulted in reduced tumor weight. This effect was mediated via the sympathetic nervous system (SNS), manifested by an attenuated noradrenergic input to a major immunological site, the bone marrow. Myeloid derived suppressor cells (MDSCs), which develop in the bone marrow, became less immunosuppressive following reward system activation. By depleting or adoptively transferring the MDSCs, we demonstrated that these cells are both necessary and sufficient to mediate reward system effects on tumor growth. Given the central role of the reward system in positive emotions, these findings introduce a physiological mechanism whereby the patient’s psychological state can impact anti-tumor immunity and cancer progression.
- 13 July 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-10
Open AccessModulation of anti-tumor immunity by the brain’s reward system
Regulating immunity is a leading target for cancer therapy. Here, we show that the anti-tumor immune response can be modulated by the brain’s reward system, a key circuitry in emotional processes. Activation of the reward system in tumor-bearing mice (Lewis lung carcinoma (LLC) and B16 melanoma) using chemogenetics (DREADDs), resulted in reduced tumor weight. This effect was mediated via the sympathetic nervous system (SNS), manifested by an attenuated noradrenergic input to a major immunological site, the bone marrow. Myeloid derived suppressor cells (MDSCs), which develop in the bone marrow, became less immunosuppressive following reward system activation. By depleting or adoptively transferring the MDSCs, we demonstrated that these cells are both necessary and sufficient to mediate reward system effects on tumor growth. Given the central role of the reward system in positive emotions, these findings introduce a physiological mechanism whereby the patient’s psychological state can impact anti-tumor immunity and cancer progression.
- Open Access
- 21 March 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (3) , e0193495
Assessment of genetic diversity, population structure, and gene flow of tigers (Panthera tigris tigris) across Nepal's Terai Arc Landscape
With fewer than 200 tigers (Panthera tigris tigris) left in Nepal, that are generally confined to five protected areas across the Terai Arc Landscape, genetic studies are needed to provide crucial information on diversity and connectivity for devising an effective country-wide tiger conservation strategy. As part of the Nepal Tiger Genome Project, we studied landscape change, genetic variation, population structure, and gene flow of tigers across the Terai Arc Landscape by conducting Nepal’s first comprehensive and systematic scat-based, non-invasive genetic survey. Of the 770 scat samples collected opportunistically from five protected areas and six presumed corridors, 412 were tiger (57%). Out of ten microsatellite loci, we retain eight markers that were used in identifying 78 individual tigers. We used this dataset to examine population structure, genetic variation, contemporary gene flow, and potential population bottlenecks of tigers in Nepal. We detected three genetic clusters consistent with three demographic sub-populations and found moderate levels of genetic variation (He = 0.61, AR = 3.51) and genetic differentiation (FST = 0.14) across the landscape. We detected 3–7 migrants, confirming the potential for dispersal-mediated gene flow across the landscape. We found evidence of a bottleneck signature likely caused by large-scale land-use change documented in the last two centuries in the Terai forest. Securing tiger habitat including functional forest corridors is essential to enhance gene flow across the landscape and ensure long-term tiger survival. This requires cooperation among multiple stakeholders and careful conservation planning to prevent detrimental effects of anthropogenic activities on tigers.
- 21 March 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (3) , e0193495
Open AccessAssessment of genetic diversity, population structure, and gene flow of tigers (Panthera tigris tigris) across Nepal's Terai Arc Landscape
With fewer than 200 tigers (Panthera tigris tigris) left in Nepal, that are generally confined to five protected areas across the Terai Arc Landscape, genetic studies are needed to provide crucial information on diversity and connectivity for devising an effective country-wide tiger conservation strategy. As part of the Nepal Tiger Genome Project, we studied landscape change, genetic variation, population structure, and gene flow of tigers across the Terai Arc Landscape by conducting Nepal’s first comprehensive and systematic scat-based, non-invasive genetic survey. Of the 770 scat samples collected opportunistically from five protected areas and six presumed corridors, 412 were tiger (57%). Out of ten microsatellite loci, we retain eight markers that were used in identifying 78 individual tigers. We used this dataset to examine population structure, genetic variation, contemporary gene flow, and potential population bottlenecks of tigers in Nepal. We detected three genetic clusters consistent with three demographic sub-populations and found moderate levels of genetic variation (He = 0.61, AR = 3.51) and genetic differentiation (FST = 0.14) across the landscape. We detected 3–7 migrants, confirming the potential for dispersal-mediated gene flow across the landscape. We found evidence of a bottleneck signature likely caused by large-scale land-use change documented in the last two centuries in the Terai forest. Securing tiger habitat including functional forest corridors is essential to enhance gene flow across the landscape and ensure long-term tiger survival. This requires cooperation among multiple stakeholders and careful conservation planning to prevent detrimental effects of anthropogenic activities on tigers.
- 18 February 2016
- Published by Taylor & Francis in OncoImmunology
- Vol. 6 (1) , e1261778
Inhibition of tumor growth and metastasis by EMMPRIN multiple antigenic peptide (MAP) vaccination is mediated by immune modulation
Previously, we have identified a new epitope in EMMPRIN, a multifunctional protein that mediates tumor cell–macrophage interactions and induces both MMP-9 and VEGF. Here, we synthesized this epitope as an octa-branched multiple antigenic peptide (MAP) to vaccinate mice implanted with subcutaneous syngeneic colon (CT26), prostate (TRAMP-C2) or renal (RENCA) cell line carcinomas. Vaccination inhibited, and sometimes regressed, tumor growth in a dose-dependent manner, reaching 94%, 71% and 72% inhibition, respectively, at a 50 μg dose (p < 0.01). Mice with regressed tumors demonstrated immune memory, preventing tumor recurrence upon re-implantation (p < 0.001). When tumor cells were administered through the tail vein to generate lung metastases, vaccination reduced the number of metastatic foci (by 15- and 23-folds, p < 0.001), and increased the median survival time by 25% and 53% in RENCA and CT26 metastases, respectively (p < 0.01) relative to scrambled-MAP controls. No significant adverse responses were observed in all experiments. We show that the tumor microenvironment was immune modulated, as vaccination induced production of EMMPRIN-specific antibodies, increased CD8+ T cells infiltration and cytotoxicity, alleviated immune suppression by decreasing TGFβ concentrations, reduced angiogenesis and cell proliferation, and enhanced apoptosis. Thus, our successful active peptide vaccination strategy differs from previous, unsuccessful attempts, both in the selected target (the EMMPRIN epitope) and in the use of a modified, MAP configuration, and demonstrates that this may be an efficient approach for the treatment and prevention of some types of cancer.
- 18 February 2016
- Published by Taylor & Francis in OncoImmunology
- Vol. 6 (1) , e1261778
Inhibition of tumor growth and metastasis by EMMPRIN multiple antigenic peptide (MAP) vaccination is mediated by immune modulation
Previously, we have identified a new epitope in EMMPRIN, a multifunctional protein that mediates tumor cell–macrophage interactions and induces both MMP-9 and VEGF. Here, we synthesized this epitope as an octa-branched multiple antigenic peptide (MAP) to vaccinate mice implanted with subcutaneous syngeneic colon (CT26), prostate (TRAMP-C2) or renal (RENCA) cell line carcinomas. Vaccination inhibited, and sometimes regressed, tumor growth in a dose-dependent manner, reaching 94%, 71% and 72% inhibition, respectively, at a 50 μg dose (p < 0.01). Mice with regressed tumors demonstrated immune memory, preventing tumor recurrence upon re-implantation (p < 0.001). When tumor cells were administered through the tail vein to generate lung metastases, vaccination reduced the number of metastatic foci (by 15- and 23-folds, p < 0.001), and increased the median survival time by 25% and 53% in RENCA and CT26 metastases, respectively (p < 0.01) relative to scrambled-MAP controls. No significant adverse responses were observed in all experiments. We show that the tumor microenvironment was immune modulated, as vaccination induced production of EMMPRIN-specific antibodies, increased CD8+ T cells infiltration and cytotoxicity, alleviated immune suppression by decreasing TGFβ concentrations, reduced angiogenesis and cell proliferation, and enhanced apoptosis. Thus, our successful active peptide vaccination strategy differs from previous, unsuccessful attempts, both in the selected target (the EMMPRIN epitope) and in the use of a modified, MAP configuration, and demonstrates that this may be an efficient approach for the treatment and prevention of some types of cancer.